ReviewFrontiers in immunology2022
The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Review
- Vaccination considerations in autoimmune rheumatic diseases.Nature reviews. Rheumatology · 2026Review
- Immunogenicity of COVID-19 booster vaccines in children receiving immunosuppressive medications.Pediatric research · 2026Observational
- Article
- Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination.Scientific reports · 2025Article
- Association between COVID-19 infection and uveitis flare in patients with Behcet's disease, a retrospective multicenter cohort study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- COVID-19 vaccine updates for people under different conditions.Science China. Life sciences · 2024Review
- Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.JCI insight · 2024Observational
- Comparison of Transient and Persistent Adverse Events After COVID-19 Vaccination: A Retrospective Analysis.Cureus · 2024Article
- Breakthrough SARS-CoV-2 infection and disease flares in patients with rheumatoid arthritis: result from COVAD e-survey study.Rheumatology international · 2024Article
- Safety of COVID-19 Vaccine in Patients with Rheumatic and Musculoskeletal Diseases.Mediterranean journal of rheumatology · 2024Article
- 4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients.Frontiers in immunology · 2024Observational
- Clinical and immunological responses to COVID-19 vaccination in rheumatoid arthritis patients on disease modifying antirheumatic drugs: a cross-sectional study.Journal of rheumatic diseases · 2024Article
- The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review.Current rheumatology reports · 2023Review
- Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study.Journal of translational autoimmunity · 2023Article
- Symptom flares after COVID-19 infection versus vaccination among youth with PANS/PANDAS.Allergy and asthma proceedings · 2023Article
- Observational
- COVID-19 vaccination experience in patients with rheumatoid arthritis treated at a single VA medical center.Vaccine: X · 2023Article
- Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study.Advances in rheumatology (London, England) · 2023Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the coronavirus disease 2019 (COVID-19) pandemic continues worldwide, vaccination has been considered an effective measure to protect people from the COVID-19 and end the pandemic. However, for patients with rheumatic diseases (RD), concern for the induction of RD flare may combat the enthusiasm for vaccination. In general, current evidence doesn't support the increased risk of disease flare after COVID-19 vaccination. However, the disease flare of RDs may be triggered by COVID-19 vaccinations, especially for patients with high disease activity. Most of these flares after vaccination are mild and need no treatment escalation. Considering the benefits and risks, RD patients are recommended to receive the COVID-19 vaccination but should be vaccinated when the RDs are in stable states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.